Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T15:27:03.692Z.
Calculation as of: 2026-10-06T15:27:03.692Z.
Quote observation: 2026-10-06T15:24:14.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6ebeba272bae7de15d59b23151f0025007a9c632b25eeddd13cd9ab927e6ebe5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Gelteq Limited Ordinary Shares
Market Cap
$5.32M
EV/EBIT Ratio
N/A
Market Cap
$5.68M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Gelteq Limited Ordinary Shares (GELS) | $5.32M | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.29M | N/A |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.27M | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.23M | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.34M | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | N/A |
| Imunon, Inc. (IMNN)vs › | $5.11M | N/A |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $5.68M | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.98M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
